A Phase 2 interventional study of PTC518 and Placebo in Huntington Disease, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 11 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 20th largest by enrollment of the 90 interventional ones that give a count, is one of 7 that started in 2022, is one of 28 in phase 2, and was the 111th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 5 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
Participants will first be randomized to Part A or Part B or Parts D or E in a 1:1 randomization ratio, depending on their Huntington's disease Integrated Staging System (HD-ISS) staging criteria and then to active treatment (PTC518 5 mg in Parts A and D and 10 mg in Parts B and E) or matching placebo within each part in a 2:1 ratio of active treatment to placebo. A Drug Safety Monitoring Board (DSMB) Charter will undertake an unblinded review of safety data from the 5 and 10 mg dosing groups and provide a recommendation on when Parts C and F (with a 20 mg active treatment arm) can be initiated. At that time, participants will be randomized to any study Part that is currently open for enrollment, and then to either active treatment or placebo (in a 2:1 ratio) within that Part.
Participants who complete this study and agree to participate in a long-term extension (LTE) study, will be enrolled in a separate LTE study PTC518-CNS-004-HD (NCT06254482).
Key Inclusion Criteria:
Eligibility for HD-ISS Stage 2 Group (Parts A, B, and C):
Eligibility for HD-ISS Mild Stage 3 Group (Parts D, E, and F):
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months.
Drug: PTC518
Participants will receive PTC518 10 mg tablets once daily orally for 12 months.
Drug: PTC518
Participants will receive PTC518 20 mg tablets once daily orally for 12 months.
Drug: PTC518
Participants will receive placebo matching to PTC518 tablets once daily orally for 12 months.
Drug: Placebo
PTC518 will be administered per dose and schedule specified in the arm.
Placebo matching to PTC518 will be administered per schedule specified in the arm.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug. A summary of other non-serious AEs and all serious adverse events (SAEs), regardless of causality is located in the 'Reported AE section'.
Time frame: Baseline up to Month 18
Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3
Least square (LS) mean and 95% confidence interval (CI) were calculated using mixed-model repeated measures (MMRM). The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
Time frame: Baseline, Month 3
Percent Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 12
LS mean and standard error (SE) were calculated using MMRM.
Time frame: Baseline, Month 12
Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 12
cUHDRS includes the Total Functional Capacity (range, 0-13; higher score means better functioning), Total Motor Score (range, 0-124; higher score means worse motor severity), Symbol Digit Modality Test (range, 0-110, correctly paired numbers-symbols in 90 seconds; higher score means better cognitive performance), and Stroop Word Reading (range, 0-no max value, correctly read colour words in 45 seconds; higher score means better cognitive performance) scores. The total score for the cUHDRS ranges from approximately 3 to 18, where higher scores indicated better functioning. LS mean and SE were calculated using analysis of covariance (ANCOVA) model.
Time frame: Baseline, Month 12
Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 12
LS mean and 95% CI were calculated using MMRM. The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
Time frame: Baseline, Month 12
Percent Change From Baseline in Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) at Month 12
LS mean and 95% CI were calculated using MMRM. The CSF mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
Time frame: Baseline, Month 12
Percent Change From Baseline in Blood mHTT Protein at Month 12
LS mean and 95% CI were calculated using MMRM. The blood mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
Time frame: Baseline, Month 12
| Milestone | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Started | 53 | 52 | 54 |
| Received at least 1 dose of study drug | 53 | 52 | 54 |
| Completed | 51 | 47 | 51 |
| Not completed | 2 | 5 | 3 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Death | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 |
| Withdrew: Study paused by sponsor in united states | 0 | 2 | 0 |
LS mean and standard error (SE) were calculated using MMRM.
| percent change | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 12 | 4.42 ± 0.413 | 4.99 ± 0.413 | 5.74 ± 0.391 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug. A summary of other non-serious AEs and all serious adverse events (SAEs), regardless of causality is located in the 'Reported AE section'.
| Participants | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 46 | 43 | 49 |
Least square (LS) mean and 95% confidence interval (CI) were calculated using mixed-model repeated measures (MMRM). The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
| percent change | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3 | -1.40 ± -7.25 | -17.36 ± -22.36 | -28.67 ± -32.74 |
cUHDRS includes the Total Functional Capacity (range, 0-13; higher score means better functioning), Total Motor Score (range, 0-124; higher score means worse motor severity), Symbol Digit Modality Test (range, 0-110, correctly paired numbers-symbols in 90 seconds; higher score means better cognitive performance), and Stroop Word Reading (range, 0-no max value, correctly read colour words in 45 seconds; higher score means better cognitive performance) scores. The total score for the cUHDRS ranges from approximately 3 to 18, where higher scores indicated better functioning. LS mean and SE were calculated using analysis of covariance (ANCOVA) model.
| units on a scale | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 12 | -0.64 ± 0.168 | -0.61 ± 0.176 | -0.92 ± 0.164 |
LS mean and 95% CI were calculated using MMRM. The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
| percent change | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 12 | 8.19 ± 1.99 | -14.18 ± -19.25 | -28.44 ± -32.45 |
LS mean and 95% CI were calculated using MMRM. The CSF mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
| percent change | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) at Month 12 | -15.64 ± -26.71 | -23.68 ± -33.97 | -23.28 ± -32.84 |
LS mean and 95% CI were calculated using MMRM. The blood mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
| percent change | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Blood mHTT Protein at Month 12 | 13.89 ± 6.33 | -14.11 ± -19.99 | -28.20 ± -32.89 |
Collected over Baseline up to Month 18. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/53 (1.9%) | 4/53 (7.5%) | 32/53 (60.4%) |
| PTC518 5 mg | 1/52 (1.9%) | 1/52 (1.9%) | 34/52 (65.4%) |
| PTC518 10 mg | 0/54 (0%) | 2/54 (3.7%) | 41/54 (75.9%) |
| Event | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| DrowningGeneral disorders and administration site conditions | 0/53 | 1/52 | 0/54 |
| Atrial fibrillationCardiac disorders | 1/53 | 0/52 | 0/54 |
| Vestibular disorderEar and labyrinth disorders | 1/53 | 0/52 | 0/54 |
| Inguinal herniaGastrointestinal disorders | 1/53 | 0/52 | 0/54 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/53 | 0/52 | 0/54 |
| Wrist fractureInjury, poisoning and procedural complications | 1/53 | 0/52 | 0/54 |
| Bone marrow oedemaBlood and lymphatic system disorders | 0/53 | 0/52 | 1/54 |
| Femur fractureInjury, poisoning and procedural complications | 0/53 | 0/52 | 1/54 |
| Event | Placebo | PTC518 5 mg | PTC518 10 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 7/53 | 8/52 | 13/54 |
| FallInjury, poisoning and procedural complications | 5/53 | 8/52 | 11/54 |
| Back painMusculoskeletal and connective tissue disorders | 4/53 | 9/52 | 8/54 |
| InfluenzaInfections and infestations | 9/53 | 7/52 | 9/54 |
| NasopharyngitisInfections and infestations | 9/53 | 6/52 | 8/54 |
| Post lumbar puncture syndromeInjury, poisoning and procedural complications | 3/53 | 5/52 | 3/54 |
| DiarrhoeaGastrointestinal disorders | 3/53 | 4/52 | 5/54 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/53 | 3/52 | 5/54 |
| COVID-19Infections and infestations | 3/53 | 2/52 | 4/54 |
| Skin abrasionInjury, poisoning and procedural complications | 1/53 | 2/52 | 4/54 |
Intent-to-treat (ITT) Population included all randomized participants who took at least 1 dose of the study drug.
| Age, Continuous(years) | Placebo | PTC518 5 mg | PTC518 10 mg | Total |
|---|---|---|---|---|
| Mean | 48.6 ± 9.59 | 49.2 ± 9.04 | 47.8 ± 9.10 | 48.5 ± 9.20 |
| Sex: Female, Male(Participants) | Placebo | PTC518 5 mg | PTC518 10 mg | Total |
|---|---|---|---|---|
| Female | 33 | 26 | 29 | 88 |
| Male | 20 | 26 | 25 | 71 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | PTC518 5 mg | PTC518 10 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 1 | 6 |
| Not Hispanic or Latino | 51 | 49 | 53 | 153 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | PTC518 5 mg | PTC518 10 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 52 | 47 | 52 | 151 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 2 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Feb 2025, 32 months.
Results were first posted in Jan 2026, 11 months after primary completion.
Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Votoplam